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Abstract
Background: Migraine carries a high global burden, disproportionately affects women, and has been implicated as
a risk factor for cardiovascular disease. Migraine with aura has been consistently associated with increased risk of
cardiovascular mortality. However, published evidence on relationships between migraine or non-migraine
headache and all-cause mortality is inconclusive. Therefore, we aimed to estimate the effect of non-migraine
headache and migraine as well as migraine subtypes on all-cause and cause-specific mortality in women.
Methods: In total, 27,844 Women’s Health Study participants, aged 45 years or older at baseline, were followed up for
a median of 22.7 years. We included participants who provided information on migraine (past history, migraine without
aura, or migraine with aura) or headache status and a blood sample at study start. An endpoints committee of
physicians evaluated reports of incident deaths and used medical records to confirm deaths due to cardiovascular,
cancer, or female-specific cancer causes. We used multivariable Cox proportional hazards models to estimate the effect
of migraine or headache status on both all-cause and cause-specific mortality.
Results: Compared to individuals without any headache, no differences in all-cause mortality for individuals suffering
from non-migraine headache or any migraine were observed after adjustment for confounding (HR = 1.01, 95%CI,
0.93–1.10 and HR = 0.96, 95% CI: 0.89–1.04). No differences were observed for the migraine subtypes and all-cause
death. Women having the migraine with aura subtype had a higher mortality due to cardiovascular disease (adjusted
HR = 1.64, 95%CI: 1.06–2.54). As an explanation for the lack of overall association with all-cause mortality, we observed
slightly protective signals for any cancer and female-specific cancers in this group.
Conclusions: In this large prospective study of women, we found no association between non-migraine headache or
migraine and all-cause mortality. Women suffering from migraine with aura had an increased risk of cardiovascular
death. Future studies should investigate the reasons for the increased risk of cardiovascular mortality and evaluate
whether changes in migraine patterns across the life course have differential effects on mortality.
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Introduction
Migraine is a common chronic, intermittent primary head-
ache disorder affecting 15% to 18% of the general adult
population, mainly affecting women [1]. According to the
2016 Global Burden of Disease data, migraine is one of the
ten most disabling disorders and is ranked second globally
for years of life lived with disability [2].
Migraine can be subdivided into migraine with aura
and migraine without aura. The migraine aura is charac-
terized by transient neurological symptoms (often lasting
5–60 min before the migraine pain), mostly affecting the
visual field [3]. Individuals with migraine have a higher
risk for multiple comorbid conditions, including cardio-
vascular disease [4–7], and some studies have linked this
added risk specifically to the aura subtype [7–9].
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We have limited knowledge regarding the association
of migraine on all-cause mortality. No overall association
was found in a 2011 meta-analysis of five pooled studies
[10]. More recently, no association with all-cause mor-
tality was observed in two large cohort studies [11, 12].
A recent Taiwanese study found that people with mi-
graine had lower all-cause mortality than individuals
without migraine, though this study did only captured
in-hospital mortality and many important sources of
confounding may have been omitted by the variable se-
lection process [13].
Given the increased risk for cardiovascular mortality but
lack of increased risk on all-cause mortality, we are led to be-
lieve there may be differential effects of having migraine in
general and of migraine aura subtypes on disease-specific
mortality. Specifically, perhaps individuals with active mi-
graine have lower risk for other cause-specific death events,
particularly female-specific cancers, as these cancers and mi-
graine are linkable to hormone levels. For these reasons, in
the present study, we aimed to estimate the effect of hav-
ing migraine or non-migraine headache, as well as specific mi-
graine subtypes on all-cause and cause-specific mortality in a
large population-based cohort study of women.
Methods
Study population
The Women’s Health Study (WHS) began as a large,
randomized, placebo-controlled trial (N = 39,876) de-
signed to test the effects of aspirin and vitamin E on the
primary prevention of cardiovascular disease (CVD) and
cancer. The design, methods, and main results of the
trial have been described in detail elsewhere [14, 15].
Briefly, at baseline (1992–1995), 39,876 US female health
professionals aged 45 years or older without a history of
cardiovascular disease, cancer, or other major illnesses
were randomized to receive low-dose aspirin (versus pla-
cebo) or vitamin E (versus placebo) in a 2-by-2 factorial
design. After the trial concluded in 2004, the study con-
tinued as a cohort design, and participants continued to
be followed on an observational basis.
Women were sent follow-up questionnaires requesting
information about demographics, lifestyle, and health in-
formation twice during the first year and annually there-
after. Written informed consent was obtained from all
participants, and the WHS was approved by the Institu-
tional Review Board at Brigham and Women’s Hospital
(clinicaltrials.gov identifier: NCT00000479).
Inclusion and exclusion criteria
At baseline, a total of 28,345 women provided venous
blood samples, of which 27,937 could be assayed for chol-
esterol levels. Of this group, we excluded participants with
missing information on the exposure (migraine or head-
ache status at baseline, N = 79). We additionally excluded
participants who died after randomization but before the
6-month questionnaire (N = 9) or for whom no question-
naire was available (N = 5), leaving us with 27,844 women
included in the present study.
Assessment of exposure: migraine and non-migraine
headache
The main exposure variable for headache was classified
into three categories: (1) no history of migraine or head-
ache, (2) non-migraine headache, or (3) any migraine.
Migraine and headache were classified as previously de-
scribed [16]. Briefly, on the baseline questionnaire, par-
ticipants were asked whether they had ever experienced
migraine headaches and whether they had had migraine
headaches in the year prior to baseline. Women
responding positively to either of these questions were
classified as having “any migraine.” Information about
non-migraine headache was asked on the questionnaire
disseminated 6 months after baseline, since there was no
question about general, non-migraine headache on the
baseline questionnaire. We classified participants as hav-
ing “non-migraine headache” if they reported headache
on the 6-month questionnaire but reported no migraine
history on the baseline questionnaire. Participants
reporting neither were classified as having “no history of
migraine or headache.”
To further classify the main exposure variable into mi-
graine subtypes, we used additional information, which
was obtained on the baseline questionnaires. For this
more detailed secondary categorization, five mutually ex-
clusive headache exposure groups were created: no
headache history, non-migraine headache, migraine with
aura, migraine without aura, and past history of mi-
graine. In an effort to avoid recall bias, we asked only
those participants who reported having migraine within
the last year about experiencing aura or any other indi-
cation that a migraine attack was coming. We classified
women who reported such phenomena as having “mi-
graine with aura”, if not, participants reporting active
migraine within the last year were classified as having
“migraine without aura.” Women who reported a past
history of migraine but no active migraine in the last
year prior to baseline were classified as having “past his-
tory of migraine.” A previous study in the WHS demon-
strated good agreement (more than 87%) between self-
reported migraine and self-reported symptoms of the
International Classification of Headache Disorders II cri-
teria [17].
Ascertainment of outcomes: all-cause and disease-specific
mortality
For the primary outcome, all reported deaths of all causes
were confirmed using information from autopsy reports,
death certificates, medical records, and information
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obtained from next of kin or family members. Disease-
specific causes of death due to cardiovascular diseases, any
cancers, or female-specific cancers, the secondary out-
comes, were confirmed by an Endpoints Committee of
physicians using medical records. Female-specific cancers
included breast cancer, cervical cancer, endometrial can-
cer, ovarian cancer, and uterine cancer.
Statistical analysis
In the present study, we computed person-time from the
time of dissemination of the 6-month questionnaire (6
months after initial randomization) to the time of death,
loss-to-follow-up, or the administrative censorship date
of December 31, 2017.
Cox proportional hazards regression models were used
to estimate hazard ratios (HRs) and corresponding 95%
confidence intervals (95% CI) for the effects of headache
status on all-cause mortality using the group of partici-
pants with no history of migraine or headache as the ref-
erence category. HRs and 95% CIs for the secondary
outcomes of cardiovascular mortality, any cancer mortal-
ity, and female-specific cancer mortality were also esti-
mated. No violations of the proportional hazard
assumption were observed upon visual inspection of the
survival distribution curves for the exposure categories
plotted over survival time. As a sensitivity analysis for
the secondary outcomes, Fine-Gray subdistribution haz-
ard models were used to account for competing risks.
For each model, any deaths due to causes other than the
cause of interest were treated as competing events.
We report results from models adjusted for age at
randomization as well as multivariable-adjusted models.
In our multivariable-adjusted models, we included the
following variables measured at baseline identified a
priori based on prior knowledge to address potential
confounding: age (in years) at randomization, body mass
index (BMI) categories based on World Health
Organization cut-offs (underweight/normal: < 25, over-
weight: 25–30, or obese: ≥30 kg/m2), total cholesterol in
Adult Treatment Panel III [18] categories (< 200, 200–
239.9, or ≥ 240 mg/dL), smoking status (never, past or
current), alcohol consumption (rarely/never, 1–3 drinks
per month, 1–6 drinks per week, or ≥ 1 drink per day),
physical activity (rarely/never, < 1 time per week, 1 to 3
times per week, ≥4 times per week), history of diabetes,
history of hypertension (self-reported history of hyper-
tension, systolic blood pressure > 140, diastolic blood
pressure > 90mmHg or prescription antihypertensive
treatment), family history of myocardial infarction in
parent aged < 60 years, and family history of cancer
(composite variable of colorectal cancer in parents or
siblings at any age, ovarian cancer in mother or sister at
any age, or breast cancer in mother or sister aged < 60
years).
Very few women were missing covariate information.
All covariates included in the multivariable models had
24 or less missing values except for family history of
myocardial infarction (N = 460), in which case we cre-
ated a separate category for women missing this infor-
mation. For the family history of cancer variable, 858
women were missing information on family history of
breast cancer and were imputed to no family history of
cancer. For the remaining categories with small numbers
of missing values, we imputed the most common or rea-
sonable value. For BMI, we imputed the mean BMI
value before categorizing (N = 23). For categorical covar-
iates, we imputed the reference category (alcohol con-
sumption, N = 6; physical activity, N = 10; history of
diabetes, N = 15; history of hypertension, N = 7) or the
past user category (smoking, N = 24).
We performed an additional post-hoc exploratory ana-
lysis to assess associations whether mortality hazards
were elevated among those with more frequent migraine
attacks. For this analysis, we categorized the exposure
into six groups: (1) no history of migraine or headache,
(2) non-migraine headache only, (3) past history of mi-
graine, (4) active migraine less than once per month in
the year before baseline, (5) active migraine about once
per month, and (6) active migraine weekly or daily.
In a further post-hoc sensitivity analysis to address po-
tential residual confounding by socioeconomic status
(SES), we created a 10-point SES index based on avail-
able income and education information, in accordance
with previously published work [19]. We re-ran the pre-
viously described multivariable models for the primary
outcome, all-cause mortality, with additional adjustment
for the SES index using the missing indicator method.
We used SAS statistical software (version 9.4) for all
analyses.
Results
Of the 27,844 participating women in this study, 5128
reported any migraine (1435 migraine with aura, 2175
migraine without aura, and 1518 past history of mi-
graine) and 4025 non-migraine headache at baseline.
Women who reported having any migraine at baseline
were generally younger, less likely to be current smokers,
consumed less alcohol and less frequently reported hav-
ing diabetes or hypertension (Table 1). We present
stratified participant characteristics by all headache and
migraine subtypes according to the secondary classifica-
tion in Additional file 1: Supplementary Table 1.
During a median of 22.7 years of follow-up (range:
0.02 to 24.1 years), a total of 5012 deaths were con-
firmed, of which 386 were due to cardiovascular disease
and 1224 were due to cancer (of these, 342 female-
specific cancer).
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In Table 2, we report the age- and multivariable-
adjusted model results for the associations between
headache or migraine status and all-cause and cause-
specific mortality. In the adjusted models, the estimated
HRs and corresponding 95% CIs for all-cause mortality
were 1.01 (0.93–1.10) for the “non-migraine headache”
group and 0.96 (0.89–1.04) for the “any migraine” group
compared to the “no history” reference group, illustrat-
ing a robustly null relationship.
In secondary analyses, we investigated the association
between migraine and cause-specific mortality from any
cancer, cardiovascular disease, or female-specific can-
cers. Among those with non-migraine headache, no
meaningful increase in mortality rate was observed for
cardiovascular mortality (HRadj = 0.99, 0.72–1.36), any can-
cer death (HRadj = 1.02, 0.86–1.21) or female-specific can-
cer mortality (HRadj = 0.87, 0.62–1.21). No relationship
was observed for the “any migraine” group with the out-
comes cardiovascular mortality (HRadj = 1.07, 0.81–1.42),
any cancer death (HRadj = 0.98, 0.84–1.15), or female-
specific cancer mortality (HRadj = 0.88, 0.65–1.19). We
used the Fine-Gray subdistribution hazard models to ac-
count for competing risks and obtained similar results
(Additional file 1: Supplementary Table 2).
For the more detailed exposure categorization includ-
ing the migraine subtypes, the HRs (95% CIs) for the pri-
mary outcome of all-cause mortality ranged from 0.91
(0.80–1.03) for the group “migraine without aura” to
Table 1 Baseline characteristics according to migraine or headache status (N = 27,844)





N = 18,691 N = 4025 N = 5128
Age, mean (SD), years 55.2 (7.3) 53.5 (6.4) 53.6 (6.4)
Body mass index, mean
(SD), kg/m2










Never 50.9 52.7 53.8
Past 37.3 35.8 35.0
Current 11.8 11.4 11.1
Alcohol consumption, %
Rarely/never 42.7 47.2 47.1
1–3 drinks/month 12.9 13.6 14.4
1–6 drinks/week 32.9 31.2 30.3
≥ 1 drink per day 11.4 8.1 8.2
Vigorous physical activity, %
Rarely/never 37.2 36.4 38.3
< 1 time/week 18.8 20.8 21.5
1–3 times/week 31.9 33.5 30.0
≥ 4 times/week 12.1 9.2 10.3
Diabetes, % 2.4 3.3 2.0
History of hypertension, % 24.8 25.3 26.2
Family history of:, %
Myocardial infarctiona 13.6 15.4 15.3
Colorectal cancerb 10.7 9.8 9.6
Ovarian cancerc 2.8 2.8 3.3
Breast cancerd 6.3 5.8 5.9
Numbers may not add up to 100% because of rounding or missing data. All variables were measured at baseline. Medical history information was self-reported
Abbreviations: SD Standard deviation, IQR Interquartile range
ain parent aged less than 60 years
bin mother, father, brother or sister at any age
cin mother or sister at any age
din mother or sister aged less than 60 years
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1.01 (0.93–1.10) for the “non-migraine headache” group
in the multivariable-adjusted models with "no history" as
the reference category (Table 3).
In the cause-specific mortality analyses (Table 3), hav-
ing migraine with aura resulted in a significantly in-
creased hazard for cardiovascular mortality compared to
the reference group of women without any headache or
migraine (HR = 1.64, 95% CI: 1.06–2.54). No other head-
ache status group had significant effects on cardiovascu-
lar death. We observed slightly protective effects of
having migraine with aura on any cancer and female-
specific cancers (HR = 0.89, 95% CI 0.67–1.19 and HR =
Table 2 Age- and multivariable-adjusted hazard ratios for all-cause and disease-specific mortality according to migraine or headache
status (N = 27,844)
Migraine or headache status: No history, (N = 18,691) Non-migraine headache, (N = 4025) Any migraine, (N = 5128)
HR -ref- HR (95% CI) HR (95% CI)
All-cause death, N 3614 641 757
Age-adjusteda 1 (ref) 1.04 (0.96–1.14) 0.95 (0.87–1.02)
Multivariable-adjustedb 1 (ref) 1.01 (0.93–1.10) 0.96 (0.89–1.04)
Cardiovascular death, N 281 46 59
Age-adjusteda 1 (ref) 1.08 (0.79–1.48) 1.05 (0.79–1.40)
Multivariable-adjustedb 1 (ref) 0.99 (0.72–1.36) 1.07 (0.81–1.42)
Cancer death, N 861 164 199
Age-adjusteda 1 (ref) 1.01 (0.86–1.20) 0.96 (0.82–1.12)
Multivariable-adjustedb 1 (ref) 1.02 (0.86–1.21) 0.98 (0.84–1.15)
Female-specific cancer deathc, N 248 41 53
Age-adjusteda 1 (ref) 0.85 (0.61–1.19) 0.86 (0.64–1.16)
Multivariable-adjustedb 1 (ref) 0.87 (0.62–1.21) 0.88 (0.65–1.19)
Abbreviations: HR Hazard ratio, CI Confidence interval, ref, reference category
a
,Adjusted for age at baseline
bAdjusted for the following variables measured at baseline: age, BMI, total cholesterol, smoking, alcohol use, physical activity, diabetes, hypertension, family
history of myocardial infarction, and family history of cancer (categorizations described in detail in the Methods)
cIncludes breast cancer, cervical cancer, endometrial cancer, ovarian cancer, and uterine cancer
Table 3 Age- and multivariable-adjusted hazard ratios for all-cause and disease-specific mortality according to migraine subtypes or











Past history of migraine,
(N = 1518)
HR -ref- HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI)
All-cause death, N 3614 641 198 253 306
Age-adjusteda 1 (ref) 1.04 (0.96–1.13) 0.96 (0.83–1.11) 0.86 (0.76–0.98) 1.02 (0.91–1.15)
MV-adjustedb 1 (ref) 1.01 (0.93–1.10) 0.99 (0.85–1.14) 0.91 (0.80–1.03) 1.00 (0.88–1.12)
Cardiovascular death, N 281 46 22 12 25
Age-adjusteda 1 (ref) 1.08 (0.79–1.47) 1.55 (1.00–2.39) 0.64 (0.36–1.14) 1.08 (0.72–1.63)
MV-adjustedb 1 (ref) 0.99 (0.72–1.35) 1.64 (1.06–2.54) 0.68 (0.38–1.22) 1.03 (0.68–1.55)
Cancer death, N 861 164 48 85 66
Age-adjusteda 1 (ref) 1.01 (0.86–1.20) 0.86 (0.64–1.15) 1.04 (0.83–1.30) 0.94 (0.73–1.20)
MV-adjustedb 1 (ref) 1.02 (0.86–1.21) 0.89 (0.67–1.19) 1.09 (0.87–1.37) 0.93 (0.72–1.19)
Female-specific cancerc
death, N
248 41 12 26 15
Age-adjusteda 1 (ref) 0.86 (0.61–1.19) 0.72 (0.40–1.29) 1.05 (0.70–1.58) 0.74 (0.44–1.25)
MV-adjustedb 1 (ref) 0.87 (0.62–1.21) 0.74 (0.41–1.32) 1.08 (0.72–1.62) 0.75 (0.45–1.27)
Abbreviations: HR Hazard ratio, CI Confidence interval, ref, reference category; MV-adjusted, multivariable-adjusted
aAdjusted for age at baseline
bAdjusted for the following variables measured at baseline: age, BMI, total cholesterol, smoking, alcohol use, physical activity, diabetes, hypertension, family
history of myocardial infarction, and family history of cancer
cIncludes breast cancer, cervical cancer, endometrial cancer, ovarian cancer, and uterine cancer
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0.74, 95% CI: 0.41–1.32), which likely explains, at least in
part, the lack of a higher all-cause mortality risk in this
group. For the detailed migraine subtype classification, the
Fine-Gray subdistribution hazard models yielded similar
results (Additional file 1: Supplementary Table 3).
We observed similar results for the complete case ana-
lysis as we did for our main analysis (results not shown).
In the post-hoc exploratory analysis, we did not observe
an association between increasing migraine frequency and
increased risk of mortality (Table 4).
In the post-hoc sensitivity analysis to address potential
residual confounding by socioeconomic status, add-
itional adjustment for SES-index yielded very similar
point estimates to the original multivariable-adjusted
models. For the main exposure categorization, the esti-
mated HRs and corresponding 95% CIs for all-cause
mortality were 1.01 (0.92–1.09) for the “non-migraine
headache” group and 0.95 (0.88–1.03) for the “any mi-
graine” group compared to the “no history” reference
group. For the detailed secondary categorization includ-
ing migraine subtypes, the HRs (95% CIs) for the pri-
mary outcome of all-cause mortality were 1.01 (0.92–
1.09) for the “non-migraine headache” group, 0.98
(0.85–1.13) for the “migraine with aura” group, 0.90
(0.79–1.03) for the group “migraine without aura”, and
0.98 (0.87–1.10) for the “past history of migraine” group.
Discussion
In this large, prospective cohort of women, we found no
association between non-migraine headache or any mi-
graine at baseline with all-cause mortality during follow-
up. Furthermore, having migraine with aura, migraine
without aura, or a past history of migraine were not
found to be associated with all-cause death. This lack of
association was apparent across all migraine frequency
groups. Women with migraine with aura had increased
hazard for cardiovascular disease-specific mortality com-
pared to those with no history of headache. There was a
suggestion that women with migraine with aura had a
lower risk of cancer mortality, which was most evident
for female-specific cancer mortality.
Comparison with other studies
Migraine and non-migraine headache have not been con-
sistently linked with an increased risk of all-cause mortal-
ity [10–12]. Some studies even suggested a decreased risk
[20]. Migraine, particularly migraine with aura, has been
linked with increased risk of cardiovascular disease in
prior reports from several individual studies [5, 6, 8, 9, 21]
and meta-analyses [4, 7].
Links between migraine and cancer have been assessed
in a few studies; these are of interest due to proposed
mechanisms of hormonal involvement for both migraine
and cancer, particularly for breast cancer [20, 22–25],
and ovarian cancer [26]. However, none of these studies
evaluated cancer-specific death as an outcome. To the
best of our knowledge, no other study has aimed to esti-
mate the effect of migraine on cancer-specific mortality.
Potential biological mechanisms that increase cardiovas-
cular mortality among women with migraine with aura are
currently unknown. Potential mechanisms that have been
proposed for the increased risk of cardiovascular disease in-
clude endovascular dysfunctions, inflammatory processes
[27], genetic susceptibility [28, 29], and mechanisms leading
to both migraine with aura and cardiovascular disease [30–
32]. Potential mechanisms linking migraine and cancer
have been mainly proposed via hormone levels [20]. How-
ever, as there is a lack of robust evidence linking migraine
and cancer, further speculative discussion about such a po-
tential link is currently not warranted.
Strengths and limitations
Strengths of our study include the large number of
women with migraine or non-migraine headache, long
follow-up period, homogeneous composition of the co-
hort, which may reduce confounding of variables related
to access to medical care, confirmed causes of death
after medical record review or existing death certificate
information, information on a number of potential con-
founding factors, and sensitivity analyses taking potential
competing risk of death by other causes into account.
Several limitations should also be considered when inter-
preting our results. First, information on migraine, migraine
characteristics, non-migraine headache, and included





















HR -ref- HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI)
All-cause death, N 3614 641 306 356 73 22
Age-adjusteda 1 (ref) 1.04 (0.96–1.13) 1.02 (0.91–1.15) 0.91 (0.82–1.02) 0.85 (0.68–1.08) 0.87 (0.58–1.33)
Multivariable-adjustedb 1 (ref) 1.01 (0.93–1.10) 1.00 (0.89–1.12) 0.94 (0.84–1.05) 0.94 (0.74–1.19) 0.92 (0.61–1.40)
Abbreviations: HR Hazard ratio, CI Confidence interval, ref., reference category
a
,Adjusted for age at baseline
bAdjusted for the following variables measured at baseline: age, BMI, total cholesterol, smoking, alcohol use, physical activity, diabetes, hypertension, family
history of myocardial infarction, and family history of cancer
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covariates were self-reported, and misclassification is pos-
sible. We cannot absolutely rule out that some of the par-
ticipants classified as having migraine with aura actually
experienced other events such as transient ischemic attacks,
which were misdiagnosed by healthcare practitioners or by
the individual participant themselves, if they did not seek
medical care. However, given the usual age of migraine on-
set compared to other vascular events with some symptom-
atic overlap, we believe that this would be a rare scenario in
our cohort.
Second, participating women were all healthcare pro-
fessionals, and results may not be fully generalizable to
other female populations and should not be extrapolated
to men.
Third, although we are not aware of any major sources
of confounding for which we lacked information, we
cannot rule out that certain comorbid conditions present
at baseline that were not assessed may have impacted
risk for migraine status at baseline as well as long-term
risk for mortality, introducing some unmeasured con-
founding. An additional post-hoc sensitivity analysis
additionally adjusting our multivariable models for SES
index yielded minimal change in the observed effect esti-
mates, suggesting that there was little residual confound-
ing due to SES as measured by the index.
Lastly, we unfortunately had no detailed information
on individual trajectories of migraine and non-migraine
headache during follow-up and thus could not estimate
the influence of patterns and changes in migraine and
non-migraine headache over time and risk of mortality.
Conclusions
In this large prospective study of women, we found no
association between non-migraine headache or migraine
(regardless of migraine aura status) and all-cause mortal-
ity. Women suffering from migraine with aura were
found to have an increased hazard for cardiovascular
death compared to women with no history of migraine
or headache. Future studies should investigate the
underlying reasons for the observed increased risk of
cardiovascular mortality for this subtype and evaluate
whether changes in migraine patterns across the life-
course may have differential effects on mortality.
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